Povidone Iodine Mouth Wash, Rinse, Gargle for C0\/lD Prevention

Povidone Iodine Mouth Wash, Rinse, Gargle for C0\/lD Prevention
by Jeffrey Dach MD

Dr. McCullough, in this interview with Peter Breggin MD (author of Talking Back to Prozac) discusses the routine use of dilute (1%) Povidone Iodine mouth wash in the dental office as an excellent preventive measure for Covid-19.

10% Povidone Iodine is available OTC (Over the Counter) without a prescription at any drug store for a few dollars.

Povidone 10%  Iodine on Amazon

Note: This 10% Povidone Iodine must be diluted to 1% strength before use as a mouth wash, otherwise it is too strong and irritating. Dilute by adding 2-3 drops of the 10% Povidone Iodine into a full glass of water.  Now it is dilute enough to use as a mouth rinse, or gargle.

Dr. McCullough recommends routine use of this mouthwash on a daily basis, and especially after contact with large indoor groups.

See this Sept 14, 2021 Dr Peter Breggin Interview with Dr Peter McCullough on Brighteon discussing Covid, vaccines, early treatment, prevention with Povidone Iodine mouth wash etc:

Jeffrey Dach MD

Articles with Related Interest:

Peter McCullough on Early Treatment vs. Vaccination

The Covid Vaccine is Safe and Effective?

CDC Director Rochelle Walensky Warns of ADE Antibody Dependent Enhancement

Ivermectin for Covid and the Failure of American Medicine

Ivermectin Anti-Cancer Anti-Parasitic Wonder Drug

Jeffrey Dach MD
7450 Griffin Road, Suite 180/190
Davie, Florida 33314

References and Links

Oronasal Hygiene with PVP-I for COVID19

Goldstein, Leo. “Oronasal Hygiene with PVP-I for COVID19.” (2021).

Arefin, Mostafa Kamal, et al. “Virucidal effect of povidone iodine on COVID-19 in the nasopharynx: an open-label randomized clinical trial.” Indian Journal of Otolaryngology and Head & Neck Surgery (2021): 1-5.

Maurya, Raj Kumar, et al. “Povidone-iodine preprocedural rinse—An evidence-based, second-line defense against severe acute respiratory coronavirus virus 2 (SARS-CoV-2) in dental healthcare.” Infection Control & Hospital Epidemiology (2021): 1-2.

Mohebbi, Simin Z., Tayebe Ebrahimi, and Ahmad Reza Shamshiri. “Do Mouthwashes Reduce Covid-19 Viral Load during Dental Procedures and Oropharyngeal Examinations? A Systematic Review.” (2021).

Ebrahimi, Tayebe, Ahmadreza SHamshiri, and Simin Z. Mohebbi. “Do mouthwashes reduce covid-19 viral load during dental procedure and oropharynge-al examination? A systematic review.” (2021).

Tadakamadla, Jyothi, et al. “In vitro studies evaluating the efficacy of mouth rinses on Sars-Cov-2: a systematic review.” Journal of Infection and Public Health (2021).

Moreno, María Victoria Mateos, et al. “ORAL ANTISEPTICS AGAINST CORONAVIRUS: IN VITRO AND CLINICAL EVIDENCE.” Journal of Hospital Infection (2021).

Chaudhary, Prem Prashant, et al. “Estimating salivary carriage of SARS-CoV2 in non-symptomatic individuals and efficacy of mouthwash in reducing viral load: a randomized controlled trial.” The Journal of the American Dental Association (2021).

Hassandarvish, Pouya, et al. “In vitro virucidal activity of povidone iodine gargle and mouthwash against SARS-CoV-2: implications for dental practice.” British dental journal (2020): 1-4.
Introduction Virus particles in respiratory droplets and aerosols generated during medical/dental procedures are a potential source of SARS-CoV-2 cross infection. In the dental setting, oral decontamination could be an important adjunct to personal protective equipment and is recommended by a number of national COVID-19 guidance documents for dental settings.

Aim To assess the in vitrovirucidal activity of an oral povidone iodine (PVP-I) product against SARS-CoV-2.

Material and methods BETADINE gargle and mouthwash (1% PVP-I) was tested against SARS-CoV-2 virus under both clean and dirty conditions using a suspension assay based on EN14476 methodology. Virucidal activity of the product, undiluted and at 1:2 dilution, was tested at contact times of 15, 30 and 60 seconds. Viral titres were calculated using the Spearman-Kärber method and reported as median tissue culture infectious dose (TCID50/ml).

Results The undiluted product achieved >5 log10 reduction in viral titres compared to the control at 15, 30 and 60 seconds under both clean and dirty conditions. At a twofold dilution (0.5% PVP-I), the test product demonstrated >4 log10 kill at 15 seconds and >5 log10 kill at 30 and 60 seconds in both clean and dirty conditions.

Conclusion PVP-I gargle and mouthwash product, undiluted and at 1:2 dilution, demonstrated potent and rapid virucidal activity (≥4 log10 reduction of viral titre) in 15 seconds against SARS-CoV-2 in vitro. The PVP-I gargle and mouthwash product is widely available and could be readily integrated into infection control measures during dental treatment including pre-procedural oral decontamination.

Bidra, Avinash S., et al. “Rapid in‐vitro inactivation of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) using povidone‐iodine oral antiseptic rinse.” Journal of Prosthodontics 29.6 (2020): 529-533.

To investigate the optimal contact time and concentration for viricidal activity of oral preparation of povidone‐iodine (PVP‐I) against SARS‐CoV‐2 (‘corona virus’) to mitigate the risk and transmission of the virus in the dental practice.
Materials and Methods

The severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) USA‐WA1/2020 strain, virus stock was tested against oral antiseptic solutions consisting of aqueous povidone‐iodine (PVP‐I) as the sole active ingredient. The PVP‐I was tested at diluted concentrations of 0.5%, 1%, and 1.5%. Test media without any virus was added to 2 tubes of the compounds to serve as toxicity and neutralization controls. Ethanol (70%) was tested in parallel as a positive control, and water only as a negative control. The test solutions and virus were incubated at room temperature (22 ± 2 °C) for time periods of 15 and 30 seconds. The solution was then neutralized by a 1/10 dilution in minimum essential medium (MEM) 2% fetal bovine serum (FBS), 50 µg/mL gentamicin. Surviving virus from each sample was quantified by standard end‐point dilution assay and the log reduction value (LRV) of each compound compared to the negative (water) control was calculated.

PVP‐I oral antiseptics at all tested concentrations of 0.5%, 1%, and 1.5%, completely inactivated SARS‐CoV‐2 within 15 seconds of contact. The 70% ethanol control group was unable to completely inactivate SARS‐CoV‐2 after 15 seconds of contact, but was able to inactivate the virus at 30 seconds of contact.

PVP‐I oral antiseptic preparations rapidly inactivated SARS‐CoV‐2 virus in vitro. The viricidal activity was present at the lowest concentration of 0.5 % PVP‐I and at the lowest contact time of 15 seconds. This important finding can justify the use of preprocedural oral rinsing with PVP‐I (for patients and health care providers) may be useful as an adjunct to personal protective equipment, for dental and surgical specialties during the COVID‐19 pandemic.

Frank, Samantha, et al. “Povidone-iodine use in sinonasal and oral cavities: a review of safety in the COVID-19 era.” Ear, Nose & Throat Journal 99.9 (2020): 586-593.

Objectives: Approaches to nasal and oral decontamination with povidone-iodine (PVP-I) have been published to reduce nosocomial spread of Severe Acute Respiratory Syndrome-Coronavirus 2 (SARS-CoV-2). The safety of PVP-I topically applied to the nasal and oral cavity is addressed by a literature review. The specific efficacy of PVP-I against coronaviruses and its potential efficacy against SARS-CoV-2 is discussed.

Methods: A review was performed utilizing PubMed and Cochrane Databases. All citations in protocols for nasal and oral PVP-I use regarding COVID-19 were independently reviewed.

Results: Povidone-iodine has been safely administered for up to 5 months in the nasal cavity and 6 months in the oral cavity. Concentrations less than 2.5% in vitro do not reduce ciliary beat frequency or cause pathological changes in ciliated nasal epithelium, upper respiratory, or mucosal cells. Adverse events with oral use have not been reported in conscious adults or children. Allergy and contact sensitivity is rare. Chronic mucosal use up to 5% has not been shown to result in clinical thyroid disease. PVP-I is rapidly virucidal and inactivates coronaviruses, including SARS-CoV and Middle East Respiratory Syndrome (MERS).

Conclusions: Povidone-iodine can safely be used in the nose at concentrations up to 1.25% and in the mouth at concentrations up to 2.5% for up to 5 months. Povidone-iodine rapidly inactivates coronaviruses, including SARS and MERS, when applied for as little as 15 seconds. There is optimism that PVP-I can inactivate SARS-CoV-2, but in vitro efficacy has not yet been demonstrated.

Published on by Jeffrey Dach MD

Leave a Reply